SOURCE: Peregrine Pharmaceuticals
TUSTIN, CA--(Marketwire - Aug 29, 2012) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the 2012 Stifel Nicolaus Healthcare Conference at The Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 5, 2012 at 2:40 PM Eastern Daylight Time.
Peregrine's presentation will be webcast live and available for replay until September 19, 2012 at: http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.